Patent classifications
C
CHEMISTRY; METALLURGY
Load children
C12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Load children
C12N
MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
Load children
C12N2710/00041
Use of virus, viral particle or viral elements as a vector
Load children Filter patents View analytics View as hierarchy Open in page
C12N2710/00045
Special targeting system for viral vectors
Filter patents View analytics View as hierarchy Open in page

C12N2710/00045

CRISPR-CAS10 SYSTEMS AND METHODS FOR PHAGE GENOME EDITING
20230041099 · 2023-02-09 ·

The present disclosure relates to CRISPR-Cas10 systems and methods for phage genome editing.

Oncolytic adenoviruses coding for bi-specific antibodies
11485791 · 2022-11-01 · ·

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to an oncolytic adenoviral vector encoding a bispecific monoclonal antibody. Furthermore, the present invention relates to methods and uses utilizing the oncolytic adenoviral vectors, also together with adoptive cell therapies.

Promoters
11261464 · 2022-03-01 ·

The present invention relates to the field of (vector) vaccines, and especially to novel promoter sequences, expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.

Crispr-CAS10 systems and methods for phage genome editing
11453892 · 2022-09-27 · ·

The present disclosure relates to CRISPR-Cas10 systems and methods for phage genome editing.

Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
20230272108 · 2023-08-31 ·

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to an oncolytic adenoviral vector encoding a bispecific monoclonal antibody. Furthermore, the present invention relates to methods and uses utilizing the oncolytic adenoviral vectors, also together with adoptive cell therapies.

CRISPR-CAS10 SYSTEMS AND METHODS FOR PHAGE GENOME EDITING
20180251787 · 2018-09-06 ·

The present disclosure relates to CRISPR-Cas10 systems and methods for phage genome editing.

PROMOTERS
20180080047 · 2018-03-22 ·

The present invention relates to the field of (vector) vaccines, and especially to novel promoter sequences, expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.

Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
20180072809 · 2018-03-15 ·

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to an oncolytic adenoviral vector encoding a bispecific monoclonal antibody. Furthermore, the present invention relates to methods and uses utilizing the oncolytic adenoviral vectors, also together with adoptive cell therapies.

Crispr-CAS10 systems and methods for phage genome editing
12378577 · 2025-08-05 · ·

The present disclosure relates to CRISPR-Cas10 systems and methods for phage genome editing.